亞盛醫藥-B(06855.HK)訂立HQP1351合作授權協議及APG-2575聯合治療戰略合作協議
格隆匯7月14日丨亞盛醫藥-B(06855.HK)發佈公吿，於2021年7月14日，公司全資附屬香港亞盛、廣州亞盛及蘇州信達訂立HQP1351合作及授權協議。據此，亞盛同意授予蘇州信達在該領域及合作區域內開發HQP1351的權利，以及在合作區域內分配至蘇州信達的城市內進行HQP1351商業化的權利。
HQP1351是公司開發的新型口服活性第三代BCR-ABL酪氨酸激酶抑制劑(TKI)，旨在有效靶向包括T315I在內的多種BCR-ABL突變體，以及中國首個開發的針對耐藥慢性髓性白血病(CML)的第三代BCR-ABLTKI。自2018年起，HQP1351的臨牀結果已連續三年入選美國臨牀腫瘤學會(ASCO)年會口頭報吿。目前，HQP1351已在中國提交新藥上市申請(NDA)，該申請隨後獲得優先審評資格。此外，HQP1351獲FDA批准進入第Ib期臨牀研究，並隨後獲FDA授予孤兒藥資格認定及快速通道資格認定。
同日，公司全資附屬蘇州亞盛及蘇州信達訂立APG-2575聯合治療戰略合作及臨牀試驗協議。據此，蘇州亞盛及蘇州信達同意抗CD20單抗、抗CD47單抗與APG-2575聯合治療某些適應症的聯合療法進行共同開發和共同開展臨牀試驗。
APG-2575是公司正在開發的新型口服小分子Bcl-2選擇性抑制劑。APG-2575旨在通過選擇性阻斷抗鉑蛋白Bcl-2以恢復癌細胞的正常細胞凋亡過程，從而治療血液惡性腫瘤及實體瘤。APG-2575是中國第一款進入臨牀開發的Bcl-2抑制劑。APG-2575迄今已在中國、美國、澳洲及歐洲獲得多項第Ib/II期臨牀研究的授權及批准，全球正在開發APG-2575以治療多種血液惡性腫瘤。作為單一藥物，APG-2575在Bcl-2依賴性腫瘤細胞系中具有有效的抗腫瘤活性，與其他抗腫瘤療法一起使用時顯示出廣泛的抗腫瘤效果。
此外，於2021年7月14日，公司及信達訂立認股權證認購契據，據此，公司同意向信達發行678.76萬份認股權證。信達毋須就認股權證支付任何代價。認股權證股份每股的初步認購價為57.20港元，較股份於2021年7月14日收市價每股52.95港元溢價約8.03%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
